Healthcare

Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), and End User (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025

  • ALL3201209
  • 210 Pages
  • May 2019
  • Healthcare
Download Sample    Get Discount   
 
The early toxicity testing market accounted for $739 million in 2017, and is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

The degree of threat posed by a chemical substance to the living organism is defined as toxicity. The branch of science that deals with measurement and further analysis of the adverse effects caused by these chemical substances on the body of an organism is called as toxicology. Toxicity testing of chemical substances is performed to select a potential drug candidate for development of newer molecules. Early toxicity is essential as it is the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Therefore, early toxicity testing is carried out at preclinical stages of a drug development process. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. There are different techniques such as in vivo, in vitro, and in silico that are employed for testing drug to monitor early toxicity associated with them. Different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others are performed using these techniques.

Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.

This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.

On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

 The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.

 A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.

 In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.

 The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Technique

• In Vivo

• In Vitro

o In Vitro Toxicity Testing Market by Assays

 Enzyme Toxicity Assays

 Bacterial Toxicity Assays

 Cell-Based ELISA and Western Blots

 Tissue Culture Assays

 Receptor Binding Assays

 Other Assays

o In Vitro Toxicity Testing Market by Toxicity Endpoints

 Dermal Toxicity

 Systemic Toxicity

 Carcinogenicity

 Ocular Toxicity

 Skin Sensitization and Irritation

 Genotoxicity

 Neurotoxicity

 Organ Toxicity

 Other Toxicity Endpoints

o In Silico

By End User

• Pharmaceuticals Industry

• Food Industry

• Chemicals Industry

• Cosmetics Industry

• Other Industries

By Region

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o France

o UK

o Rest of Europe

• Asia-Pacific

o India

o China

o Japan

o Australia

o Rest of Asia-Pacific

• LAMEA

o Brazil

o South Africa

o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Agilent Technologies, Inc.

• General Electric Company (GE Healthcare)

• Danaher Corporation (Beckman Coulter, Inc.)

• Evotec AG (Cyprotex)

• Bioanalytical Systems, Inc.

• Bruker Corporation

• Thermo Fisher Scientific, Inc.

• PerkinElmer Inc.

• Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)

• Myriad Genetics, Inc. (Myriad RBM.)

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

• Randox Toxicology

• Geneva Laboratories, Inc.

Advanced Chemistry Development (ACD/Labs)

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017

3.4. Porter’s five forces analysis

3.5. Government regulations

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Surge in R&D activities in healthcare

3.6.1.2. Rise in adoption of in vitro model

3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare

3.6.1.4. Surge in adoption of early toxicity testing

3.6.2. Restraint

3.6.2.1. Limitations of preclinical testing

3.6.3. Opportunity

3.6.3.1. Technological advancement in the field of early toxicity testing

3.6.4. Impact analysis

CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. Overview

4.1.1. Market size and forecast

4.2. In Vivo

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. In Vitro

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

4.3.4. In vitro early toxicity testing market, by assay

4.3.4.1. Enzyme toxicity assays

4.3.4.1.1. Market size and forecast

4.3.4.2. Bacterial toxicity assays

4.3.4.2.1. Market size and forecast

4.3.4.3. Cell-based ELISA and western blots

4.3.4.3.1. Market size and forecast

4.3.4.4. Tissue culture assays

4.3.4.4.1. Market size and forecast

4.3.4.5. Receptor binding assays

4.3.4.5.1. Market size and forecast

4.3.4.6. Others

4.3.4.6.1. Market size and forecast

4.3.5. In vitro early toxicity testing market, by toxicity end-point

4.3.5.1. Dermal toxicity

4.3.5.1.1. Market size and forecast

4.3.5.2. Systemic toxicity

4.3.5.2.1. Market size and forecast

4.3.5.3. Carcinogenicity

4.3.5.3.1. Market size and forecast

4.3.5.4. Ocular toxicity

4.3.5.4.1. Market size and forecast

4.3.5.5. Skin sensitization and irritation

4.3.5.5.1. Market size and forecast

4.3.5.6. Genotoxicity

4.3.5.6.1. Market size and forecast

4.3.5.7. Neurotoxicity

4.3.5.7.1. Market size and forecast

4.3.5.8. Organ toxicity

4.3.5.8.1. Market size and forecast

4.3.5.9. Others

4.3.5.9.1. Market size and forecast

4.4. In silico

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

5.1. Overview

5.1.1. Market size and forecast

5.2. Pharmaceutical industry

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

5.3. Food industry

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Chemicals industry

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

5.5. Cosmetic industry

5.5.1. Market size and forecast, by region

5.5.2. Market analysis, by country

5.6. Others

5.6.1. Market size and forecast, by region

5.6.2. Market analysis, by country

CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. early toxicity testing market, by technique type

6.2.2.1.2. U.S. early toxicity testing market, by end user

6.2.2.2. Canada

6.2.2.2.1. Canada early toxicity testing market, by technique type

6.2.2.2.2. Canada early toxicity testing market, by end user

6.2.2.3. Mexico

6.2.2.3.1. Mexico early toxicity testing market, by technique type

6.2.2.3.2. Mexico early toxicity testing market, by end user

6.2.3. Market size and forecast, by technique type

6.2.4. Market size and forecast, by end user

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany early toxicity testing market, by technique type

6.3.2.1.2. Germany early toxicity testing market, by end user

6.3.2.2. France

6.3.2.2.1. France early toxicity testing market, by technique type

6.3.2.2.2. France early toxicity testing market, by end user

6.3.2.3. UK

6.3.2.3.1. UK early toxicity testing market, by technique type

6.3.2.3.2. UK early toxicity testing market, by end user

6.3.2.4. Rest of Europe

6.3.2.4.1. Rest of Europe early toxicity testing market, by technique type

6.3.2.4.2. Rest of Europe early toxicity testing market, by end user

6.3.3. Market size and forecast, by technique type

6.3.4. Market size and forecast, by end user

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan early toxicity testing market, by technique type

6.4.2.1.2. Japan early toxicity testing market, by end user

6.4.2.2. China

6.4.2.2.1. China early toxicity testing market, by technique type

6.4.2.2.2. China early toxicity testing market, by end user

6.4.2.3. Australia

6.4.2.3.1. Australia early toxicity testing market, by technique type

6.4.2.3.2. Australia early toxicity testing market, by end user

6.4.2.4. India

6.4.2.4.1. India early toxicity testing market, by technique type

6.4.2.4.2. India early toxicity testing market, by end user

6.4.2.5. Rest of Asia-Pacific

6.4.2.5.1. Rest of Asia-Pacific early toxicity testing market, by technique type

6.4.2.5.2. Rest of Asia-Pacific early toxicity testing market, by end user

6.4.3. Market size and forecast, by technique type

6.4.4. Market size and forecast, by end user

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil early toxicity testing market, by technique type

6.5.2.1.2. Brazil early toxicity testing market, by end user

6.5.2.2. South Africa

6.5.2.2.1. South Africa early toxicity testing market, by technique type

6.5.2.2.2. South Africa early toxicity testing market, by end user

6.5.2.3. Rest of LAMEA

6.5.2.3.1. xx early toxicity testing market, by technique type

6.5.2.3.2. rest of LAMEA early toxicity testing market, by end user

6.5.3. Market size and forecast, by technique type

6.5.4. Market size and forecast, by end user

CHAPTER 7: COMPANY PROFILES

7.1. AGILENT TECHNOLOGIES, INC.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product type Portfolio

7.1.5. Business performance

7.2. BIOANALYTICAL SYSTEMS, INC.

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.3. BRUKER CORPORATION

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product portfolio

7.3.5. Business performance

7.4. DANAHER CORPORATION (BECKMAN COULTER, INC.)

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product type portfolio

7.4.5. Business performance

7.5. EVOTEC AG (CYPROTEX)

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product portfolio

7.5.5. Business performance

7.6. ENZO BIOCHEM, INC. (ENZO CLINICAL LABS, INC.)

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product Portfolio

7.6.5. Business performance

7.7. GENERAL ELECTRIC COMPANY (GE HEALTHCARE)

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product portfolio

7.7.5. Business performance

7.8. MYRIAD GENETICS, INC. (MYRIAD RBM.)

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Product Portfolio

7.8.4. Business performance

7.9. PERKINELMER INC.

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

7.10. THERMO FISHER SCIENTIFIC, INC.

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)

TABLE 02. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 03. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)

TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINT, 2017–2025 ($MILLION)

TABLE 06. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)

TABLE 07. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)

TABLE 08. EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)

TABLE 09. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2017–2025 ($MILLION)

TABLE 10. EARLY TOXICITY TESTING MARKET FOR CHEMICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)

TABLE 11. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY REGION, 2017–2025 ($MILLION)

TABLE 12. EARLY TOXICITY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2017–2025 ($MILLION)

TABLE 13. EARLY TOXICITY TESTING MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)

TABLE 14. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 15. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 16. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 17. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 18. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 19. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 20. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 21. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 22. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 23. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 28. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 30. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 31. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 32. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 33. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 34. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 35. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 36. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 37. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 38. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 39. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 40. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 41. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 42. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 43. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 45. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 46. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 47. LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)

TABLE 48. BRAZIL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 49. BRAZIL EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 50. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 51. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 52. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 53. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 54. LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025

TABLE 55. LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025

TABLE 56. AGILENT: COMPANY SNAPSHOT

TABLE 57. AGILENT: OPERATING SEGMENTS

TABLE 58. AGILENT: PRODUCT TYPE PORTFOLIO

TABLE 59. BASI: COMPANY SNAPSHOT

TABLE 60. BASI: OPERATING SEGMENTS

TABLE 61. BASI: PRODUCT PORTFOLIO

TABLE 62. BRUKER: COMPANY SNAPSHOT

TABLE 63. BRUKER: OPERATING SEGMENTS

TABLE 64. BRUKER: PRODUCT PORTFOLIO

TABLE 65. DANAHER: COMPANY SNAPSHOT

TABLE 66. DANAHER: OPERATING SEGMENTS

TABLE 67. DANAHER: PRODUCT TYPE PORTFOLIO

TABLE 68. EVOTEC: COMPANY SNAPSHOT

TABLE 69. EVOTEC: OPERATING SEGMENTS

TABLE 70. EVOTEC: PRODUCT PORTFOLIO

TABLE 71. ENZO: COMPANY SNAPSHOT

TABLE 72. ENZO: OPERATING SEGMENTS

TABLE 73. ENZO: PRODUCT PORTFOLIO

TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT

TABLE 75. GE HEALTHCARE: OPERATING SEGMENTS

TABLE 76. GE HEALTHCARE: PRODUCT PORTFOLIO

TABLE 77. MYRIAD: COMPANY SNAPSHOT

TABLE 78. MYRIAD: PRODUCT PORTFOLIO

TABLE 79. PERKINELMER: COMPANY SNAPSHOT

TABLE 80. PERKINELMER: OPERATING SEGMENTS

TABLE 81. PERKINELMER: PRODUCT PORTFOLIO

TABLE 82. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 83. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 84. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...

  • Publish Date: May 29, 2018
  • $5370
World Medical Robotics and Computer - Assisted Surgery Market - Opportunities and Forecasts, 2015 - 2022

The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...

  • Publish Date: May 1, 2016
  • $5370